# Hookipa Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hookipa-biotech

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.hookipapharma.com/
- Total disclosed funding: $144M
- Latest round: Series D (Feb 26, 2019)
- Investors on record: 13

## About

Founded in 2011 and headquartered in New York, US, Hookipa Biotech GmbH specializes in immunotherapy development. In December 2023, Gilead Sciences, Inc. acquired a minority stake in Hookipa Biotech GmbH from Samsara BioCapital, Redmile Group, Invus, Baker Brothers Advisors LLC, Sirona Capital, Hillhouse Capital Management, HBM Partners, Takeda Ventures, Boehringer Ingelheim Venture, BioMed Partners, Sofinnova Partners and Forbion for USD 21.25 million in stock at USD 1.47 per share. The company may sell an additional $8.75 million of common stock to Gilead Sciences, Inc., subject to certain terms and conditions. Following the deal, Gilead Sciences, Inc. will hold a 19.4% minority stake in Hookipa Biotech GmbH. The acquisition enables Gilead Sciences, Inc. to advance its HIV program through Phase 1 trial.

Hookipa Pharma specializes in developing innovative immunotherapy solutions aimed at reprogramming the immune system to effectively target and combat cancer and infectious diseases. Their proprietary arenaviral platform is designed to engineer therapeutics that amplify the body’s natural immune response, specifically focusing on mobilizing CD8+ T cells and antibodies. These therapeutics enhance the specificity, quantity, and quality of immune responses, addressing significant unmet medical needs in oncology and infectious disease treatment. Their product offerings primarily target healthcare providers, research institutions, and pharmaceutical partners across North America, Europe, and select regions in Asia, where advanced cancer therapies are in demand, benefiting patients affected by various types of cancers and infectious diseases.

## Funding rounds

- Series D, Feb 26, 2019, $38M — Invus [DUP], Redmile Group, Takeda Ventures, Samsara BioCapital, Baker Brothers Advisors LLC
- Series C, Dec 9, 2017, $70M — Sofinnova Partners, HBM Partners, BioMed Partners, Forbion, Boehringer Ingelheim Venture, Gilead Sciences, Inc., Hillhouse Investment, Takeda Ventures, Sirona Capital
- Series B, Nov 4, 2013, $27M — Sofinnova Partners, BioMed Partners, Forbion, Boehringer Ingelheim Venture, Takeda Ventures
- Series A, Sep 30, 2011, $9.6M — Sofinnova Partners, Forbion

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B, Series C
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A, Series B, Series C
- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series B, Series C
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series B, Series C
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series B, Series C, Series D
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C
- Gilead Sciences, Inc. — Series C
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series C
- Sirona Capital (https://capitalatlas.ai/funds/sirona-capital) — Series C
- Invus [DUP] — Series D
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series D
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series D
- Baker Brothers Advisors LLC — Series D